宁夏中科生物科技股份有限公司 关于召开 2023 年第三次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600165 证券简称：宁科生物 公告编号：2023-051 网络投票起止时间：自 2023 年 11 月 13 日 至 2023 年 11 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 1 股东大会召开日期：2023年11月13日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 一、 召开会议的基本情况 网络投票系统：上海证券交易所股东大会网络投票系统 本次股东大会审议议案及投票股东类型 | 序号 | 议案名称 | 投票股东类型 | | --- | --- | --- | | | | 股股东 A | | 非累积投票议案 | | | | 1 | 关于 ...

证券代码：600165 股票简称：宁科生物 公告编号：临 2023-050 宁夏中科生物科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 拟续聘的会计师事务所名称：信永中和会计师事务所（特殊普通合伙）（以下 简称：信永中和）。 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 名 称：信永中和会计师事务所（特殊普通合伙） 成立日期：2012 年 3 月 2 日 组织形式：特殊普通合伙企业 注册地址：北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层 首席合伙人：谭小青先生 截至 2022 年 12 月 31 日，信永中和合伙人（股东）249 人，注册会计师 1,495 人。签署过证券服务业务审计报告的注册会计师人数超过 660 人。 2、投资者保护能力 信永中和已按照有关法律法规要求投保职业保险，职业保险累计赔偿限额和职 业风险基金之和超过 2 亿元，职业风险基金计提或职业保险购买符合相关规定。除 乐视网证券虚假陈述责任纠纷一案之外，信永中和近 ...

本次立案事项系对虞建明先生个人的调查，公司目前生产经营情况正常。在立 案调查期间，虞建明先生将积极配合中国证监会的相关工作，公司将持续关注上述 事项的进展情况，严格按照有关法律、法规的规定履行信息披露义务。 公司指定信息披露媒体为《上海证券报》、《证券时报》，指定信息披露网站为上 海证券交易所网站（www.sse.com.cn），公司发布的信息以在上述指定媒体、网站刊 登的公告为准。敬请广大投资者注意投资风险。 证券代码：600165 股票简称：宁科生物 公告编号：临 2023-048 宁夏中科生物科技股份有限公司 关于实际控制人收到中国证券监督管理委员会 立案告知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁夏中科生物科技股份有限公司（以下简称：公司）接到实际控制人虞建明先 生通知，虞建明先生于 2023 年 9 月 7 日收到中国证券监督管理委员会（以下简称： 中国证监会）下发的《立案告知书》（编号：证监立案字 0342023004 号），因涉嫌信 息披露违法违规，中国证监会决定对虞建明先生立案。 特此公告。 ...

证券代码：600165 股票简称：宁科生物 公告编号：临 2023-047 宁夏中科生物科技股份有限公司 重大诉讼公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 案件所处的诉讼阶段：立案受理，尚未开庭。 ● 是否会对上市公司损益产生负面影响：鉴于案件尚未审理，目前无法准 确判断对宁夏中科生物科技股份有限公司（以下简称：公司）本期利润或期后 利润的影响，最终影响以法院审理结果为准。 ● 法院出具的财产保全裁定书，仅为相关方采取的财产保全措施，公司目 前生产经营情况正常。 一、本次重大诉讼的基本情况 因股权转让合同纠纷，公司控股子公司宁夏中科生物新材料有限公司（以下 简称：中科新材）股东宁夏产业引导基金管理中心（有限公司）（以下简称：产 业基金）作为原告向宁夏回族自治区银川市中级人民法院（以下简称：银川市中 院）提交了《民事起诉状》，对被告上海中能企业发展(集团)有限公司（以下简 称：上海中能）、公司、中科新材提起诉讼。 二、本次重大诉讼的案件当事人、诉讼请求、事实及理由、案件进展情况 （一）案件当事人 ...

宁夏中科生物科技股份有限公司（以下简称：公司）于 2023 年 8 月 24 日收到 公司控股股东上海中能企业发展（集团）有限公司通知，公司实际控制人虞建明先 生曾于 2020 年 7 月因涉及操纵证券市场事项，为配合调查被有权机关采取强制措施， 上海市人民检察院第一分院于 2021 年 3 月 26 日受理该案件，涉及主体为上海中能 企业发展（集团）有限公司、虞建明先生以及其他 6 名自然人，2023 年 3 月 9 日上 海市人民检察院第一分院向虞建明先生出具沪检一分刑不诉【2023】12 号文书："经 本院审查并经二次退回补充侦查，本院仍然认为上海市公安局认定的犯罪事实不清、 证据不足，不符合起诉条件，依照《中华人民共和国刑事诉讼法》第一百七十五条 第四款的规定，决定对虞建明不起诉。"目前上述案件正在审理中，公司将持续关注 上述事项进展情况，严格按照有关法律、法规的规定履行信息披露义务。 公司目前生产经营情况正常，各项工作有序开展。公司指定信息披露媒体为《上 海 证 券 报 》、《 证 券 时 报 》， 指 定 信 息 披 露 网 站 为 上 海 证 券 交 易 所 网 站 （www.sse.com.c ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥101.99 million, a decrease of 78.54% compared to ¥475.30 million in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2023 was a loss of approximately ¥136.77 million, compared to a profit of ¥8.91 million in the same period last year, representing a decrease of 1,635.28%[18]. - The net cash flow from operating activities for the first half of 2023 was a negative ¥25.31 million, a decline of 361.39% compared to ¥9.68 million in the same period last year[19]. - The basic earnings per share for the first half of 2023 was -¥0.200, compared to ¥0.013 in the same period last year, a decrease of 1,638.46%[20]. - The weighted average return on net assets for the first half of 2023 was -24.383%, a decrease of 25.539 percentage points compared to 1.156% in the same period last year[20]. - The company reported a net loss of ¥154,054,023.08 for the first half of 2023, compared to a net profit of ¥7,241,442.69 in the first half of 2022, indicating a substantial decline in profitability[104]. - The total comprehensive loss for the first half of 2023 was ¥154,033,669.22, compared to a comprehensive income of ¥7,475,957.93 in the same period of 2022[104]. Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥3.15 billion, a decrease of 3.96% from ¥3.28 billion at the end of the previous year[19]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥492.56 million, down 21.73% from ¥629.31 million at the end of the previous year[19]. - Cash and cash equivalents decreased by 76.21% to ¥21,288,694.26, primarily due to payment of goods[41]. - Accounts receivable financing decreased by 40.26% to ¥1,389,724.25, mainly due to payments made by the subsidiary[41]. - Other current assets decreased by 83.31% to ¥355,307.82, attributed to VAT refund received by the subsidiary[41]. - Total liabilities increased from CNY 2,384,616,750.65 to CNY 2,408,713,236.66, an increase of about 1.01%[96]. - Current liabilities rose from CNY 1,566,516,438.06 to CNY 1,638,307,854.67, an increase of about 4.57%[96]. Operational Insights - The company aims to enhance its profitability by continuously expanding its market share and aligning with market demand[28]. - The company employs a mixed sales model combining direct sales, distribution, and consignment to enhance market penetration[28]. - The procurement process involves selecting multiple suppliers to ensure cost control and stable raw material supply[28]. - The company has detailed the potential risks in the "Management Discussion and Analysis" section of the report[4]. - The company has established a support plan with the local government to help Zhongke New Materials recover from financial difficulties[136]. Environmental Compliance - The company invested nearly 400 million yuan in environmental protection facilities to comply with national regulations and reduce wastewater discharge[57]. - The company has achieved compliance with pollutant discharge standards, with no major environmental issues reported during the reporting period[58]. - The company has implemented various pollution control systems, including advanced technologies for gas and wastewater treatment[59]. - The company has developed a self-monitoring plan for environmental compliance, with third-party assessments confirming that all discharge indicators meet standards[62]. Government Support and Financial Assistance - The company secured special relief funds from the local government to support its subsidiary, which has resumed production[35]. - The company signed a cooperation agreement for financial assistance with the local government to support its subsidiary, Zhongke New Materials[82]. - The company has successfully raised special relief funds through the Shizuishan Huinong District government financing platform to support Zhongke New Materials[68]. Shareholder Information - Total number of common shareholders as of the end of the reporting period is 33,308[86]. - The largest shareholder, Shanghai Zhongneng Enterprise Development (Group) Co., Ltd., holds 200,000,000 shares, accounting for 29.20% of total shares[87]. - The second-largest shareholder, Feng Liang, holds 27,392,229 shares, representing 4.00% of total shares[87]. Legal and Regulatory Matters - The company received a warning letter from the China Securities Regulatory Commission on June 1, 2023, due to regulatory violations, and has implemented corrective measures to enhance compliance awareness[72]. - The company is involved in significant litigation related to financial loan agreements, with Ningxia State-owned Assets Investment Holding Group filing a lawsuit against multiple parties including the company[70]. Financial Management and Accounting Policies - The company’s financial statements are prepared based on the principle of going concern, reflecting its financial position and operating results accurately[138]. - The company’s accounting policies are tailored to its operational characteristics, including revenue recognition and inventory measurement[137]. - The company includes all controlled subsidiaries in the consolidated financial statements, adjusting for any inconsistencies in accounting policies or periods[143]. Research and Development - Research and development expenses decreased by 64.96% to CNY 5.54 million, reflecting reduced investment from the subsidiary[38]. - The company has not reported any new product launches or technological advancements in the current period[127].

证券代码：600165 股票简称：宁科生物 公告编号：临 2023-045 宁夏中科生物科技股份有限公司 | 单位：万元 | | --- | 关于上海证券交易所对公司 2022 年年度报告 事后问询函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁夏中科生物科技股份有限公司（以下简称：公司）于2023年5月19日收到上海 证券交易所《关于宁夏中科生物科技股份有限公司2022年年度报告的事后审核问询函》 （上证公函【2023】0569号）（以下简称：《问询函》）（具体详见：临2023-027号 公告），于2023年6月17日披露了《关于上海证券交易所对公司2022年年度报告事后 问询函的部分回复公告》（具体详见：临2023-034号公告），现将《问询函》中未披 露的问题第4、5项回复如下。本次回复后，公司对上证公函【2023】0569号《问询函》 的所有问题全部予以回复并披露。 4.关于流动性风险。公司流动性负债规模从 10.8 亿元上升至 15.67 亿元，公司一 年内到期的非流动负债有 3.7 亿元，同比增长 ...

证券代码：600165 股票简称：宁科生物 公告编号：临 2023-025 宁夏中科生物科技股份有限公司 关于召开 2022 年度网上业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 17 日（星期三）10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 报 中 国 证 券 网 路 演 中 心 （ 网 址 ： http://roadshow.cnstock.com/） 会议召开方式：网络互动 1 http://roadshow.cnstock.com/） （三）会议召开方式：网络互动 三、参加人员 投资者可于 2023 年 5 月 15 日（星期一）17:00 前将相关问题通过电子邮 件的形式发送至公司邮箱：official@ningkeshengwu.com。公司将在信息披露允 许范围内，在 2022 年度网上业绩说明会对投资者普遍关注的问题进行回答。 宁夏中科生物科技股份有限公司（以下简称：公司）已于 2023 年 4 月 28 日发布公司 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥46,109,368.75, representing a decrease of 72.34% compared to the same period last year[3] - The net profit attributable to shareholders was -¥58,433,529.67, indicating a significant loss[3] - The company reported a basic and diluted earnings per share of -¥0.085[3] - The weighted average return on equity was -9.737%[3] - Total revenue for Q1 2023 was CNY 46,109,368.75, a decrease of 72.5% compared to CNY 166,716,293.63 in Q1 2022[16] - Net loss for Q1 2023 was CNY 66,686,256.61, compared to a net loss of CNY 27,903,539.27 in Q1 2022, representing a 139.2% increase in losses[17] - Basic and diluted earnings per share for Q1 2023 were both CNY -0.085, compared to CNY -0.034 in Q1 2022[18] - Total equity attributable to shareholders was CNY 571,150,551.54, down from CNY 629,309,835.41 in Q1 2022, a decrease of 9.2%[16] Cash Flow and Liquidity - The net cash flow from operating activities was -¥42,832,422.48, reflecting a decline in cash generation[3] - Operating cash flow for Q1 2023 was negative CNY 42,832,422.48, an improvement from negative CNY 87,572,135.13 in Q1 2022[18] - Cash inflow from operating activities was CNY 55,549,016.24 in Q1 2023, compared to CNY 162,513,832.34 in Q1 2022, a decline of 65.9%[18] - The company's cash and cash equivalents decreased to ¥35,779,145.22 from ¥89,483,876.89, representing a significant decline of approximately 60%[13] - The cash and cash equivalents at the end of the period were 9,415,253.24, down from 26,318,342.47 in the prior period[19] - The company reported a net decrease in cash and cash equivalents of -33,789,917.96, compared to -66,679,303.33 in the prior period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,216,319,042.22, down 1.90% from the previous year-end[4] - Total liabilities as of Q1 2023 were CNY 2,388,649,968.19, slightly up from CNY 2,384,616,750.65 in Q1 2022[16] - Shareholders' equity attributable to the company was ¥571,150,551.54, a decrease of 9.24% compared to the previous year-end[4] - The company's non-current assets totaled ¥3,007,334,369.72, down from ¥3,026,839,472.43, indicating a decrease of about 0.6%[14] Operational Challenges - The company is currently facing risks related to the temporary suspension of operations at its subsidiary, Zhongke New Materials, due to a breach of capital contribution agreement by Jinan Changyue, which has led to a halt in production[10] - The company is actively seeking financing solutions to address the operational challenges at Zhongke New Materials and aims to resume production within three months[11] - The company has disclosed that it will not pursue preferential subscription rights in the capital increase of its subsidiary, Zhongke New Materials, which may impact future capital structure and funding strategies[10] Changes in Expenses and Receivables - The company experienced a 90.33% increase in prepayments, primarily due to advance payments for technical services by its subsidiary[7] - The company’s sales expenses decreased by 43.55%, attributed to a decline in sales volume at its subsidiary[7] - Accounts receivable decreased to ¥27,483,532.85 from ¥32,676,410.20, a reduction of about 16%[13] - Inventory increased to ¥112,904,551.57 from ¥109,305,912.49, showing a slight increase of approximately 2.4%[14] Financing Activities - Cash inflow from financing activities totaled 188,400,000.00, an increase from 153,980,498.05 in the prior period[19] - The company received 134,600,000.00 in borrowings, up from 115,000,000.00 in the previous period[19] - The net cash flow from financing activities was 9,824,818.42, a decrease from 29,394,200.76 in the previous period[19]

Group 1: Event Details - The company will participate in the "2023 Ningxia Listed Companies Investor Collective Reception Day" [2] - The event will be held online on May 11, 2023, from 14:00 to 17:00 [2] - Investors can join via the "Panjing Roadshow" website, WeChat public account, or the Panjing Roadshow APP [2] Group 2: Company Representatives - The company's General Manager, CFO, and Board Secretary will be present to communicate with investors [2] - Topics of discussion will include the company's 2022 performance, governance, development strategy, operational status, financing plans, equity incentives, and sustainable development [2] Group 3: Investor Engagement - The company encourages active participation from investors during the event [2] - The initiative aims to strengthen interaction and communication with investors [2]